• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » COVID-19 assays sales power Hologic to Street-beating Q1

COVID-19 assays sales power Hologic to Street-beating Q1

January 27, 2021 By Sean Whooley

HologicHologic (NSDQ:HOLX) shares ticked up after hours today on first-quarter results that topped the consensus forecast.

The Marlborough, Mass.-based company posted profits of $653.4 million, or $2.50 per share, on sales of $1.6 billion for the three months ended Dec. 26, 2020, for a 69.4% bottom-line gain on sales growth of 89.3%.

Adjusted to exclude one-time items, earnings per share were $2.86, 69¢ ahead of Wall Street, where analysts were looking for sales of $1.4 billion.

Hologic continues to benefit from demand for its two COVID-19 assays that run on its Panther and Panther Fusion systems as its worldwide molecular diagnostics business brought in $995.3 million for an increase of 457.6% year-over-year.

“Hologic had a strong start to fiscal 2021 across all our businesses and major geographies,” Hologic chairman, president & CEO Steve MacMillan said in a news release. “Our Diagnostics division continued to deliver incredible performance by making a massive impact against COVID-19. Furthermore, our Breast Health and Surgical businesses continued to strengthen, with each returning to growth in the United States, Europe and Asia-Pacific.”

The company has recently been active on the mergers & acquisitions front, too, having executed the acquisition of Somatex Medical Technologies GmbH and its minimally invasive devices for tumor diagnostics, biopsy and interventional specialties in breast health for $64 million, followed by the purchase of molecular diagnostic test maker Biotheranostics for approximately $230 million, all in the space of two weeks.

Hologic said it now expects to log second-quarter adjusted EPS of between $2.56 and $2.68 while setting its sales guidance for between $1.5 billion and $1.56 billion.

HOLX  shares were up 2.4% after hours at $74.25 per share, having closed the day down -2.7% at $72.51. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down -2%.

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, MassDevice Earnings Roundup, Wall Street Beat, Women's Health Tagged With: coronavirus, COVID-19, Hologic

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy